Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
July 25, 2017 1:51 PM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $67.00 (from $62.00) while maintaining a Outperform rating.
Analyst Do Kim recommends buying on weakness following Biogen comments on Spinraza growth to slow in 2H17.
"We believe Spinraza has... More
Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
July 25, 2017 12:05 PM EDTNeedham & Company analyst Chad Messer is telling clients to buy Ionis Pharmaceuticals (NASDAQ: IONS) on weakness as growth concerns overlook the longer-term opportunity.
Messer notes partner Biogen reported $203M in 2Q SPRINRAZA sales, a dramatic increase from $47M in 1Q... More
